827 related articles for article (PubMed ID: 31558879)
1.
Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
[TBL] [Abstract][Full Text] [Related]
2. Hot-topic debate on tolerance: immunosuppression withdrawal.
Sánchez-Fueyo A
Liver Transpl; 2011 Nov; 17 Suppl 3():S69-73. PubMed ID: 21850680
[TBL] [Abstract][Full Text] [Related]
3. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
4. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
Jain A; Reyes J; Kashyap R; Rohal S; Abu-Elmagd K; Starzl T; Fung J
Ann Surg; 1999 Sep; 230(3):441-8; discussion 448-9. PubMed ID: 10493490
[TBL] [Abstract][Full Text] [Related]
5. Tolerance after liver transplantation: Where are we?
Feng S; Bucuvalas J
Liver Transpl; 2017 Dec; 23(12):1601-1614. PubMed ID: 28834221
[TBL] [Abstract][Full Text] [Related]
6. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
7. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation.
Aseni P; Vertemati M; De Carlis L; Sansalone CV; Bonacina E; Minola E; Oreste P; Vizzotto L; Rondinara G
Pathol Int; 2006 Nov; 56(11):712-5. PubMed ID: 17040297
[TBL] [Abstract][Full Text] [Related]
8. De novo malignancy after lung transplantation in Japan.
Miyazaki T; Oto T; Okumura M; Date H; Shiraishi T; Okada Y; Chida M; Kondo T; Nagayasu T
Gen Thorac Cardiovasc Surg; 2016 Sep; 64(9):543-8. PubMed ID: 27270709
[TBL] [Abstract][Full Text] [Related]
9. National survey of de novo malignancy after solid organ transplantation in Japan.
Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review.
Chak E; Saab S
Liver Int; 2010 Oct; 30(9):1247-58. PubMed ID: 20602682
[TBL] [Abstract][Full Text] [Related]
11. Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization.
Sarwal MM
Clin Biochem; 2016 Mar; 49(4-5):404-10. PubMed ID: 26794635
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
[TBL] [Abstract][Full Text] [Related]
13. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.
de la Garza RG; Sarobe P; Merino J; Lasarte JJ; D'Avola D; Belsue V; Delgado JA; Silva L; Iñarrairaegui M; Sangro B; Sola JJ; Pardo F; Quiroga J; Herrero JI
Liver Transpl; 2013 Sep; 19(9):937-44. PubMed ID: 23784747
[TBL] [Abstract][Full Text] [Related]
14. Prope tolerance after pediatric liver transplantation: Experience at Shiraz Organ Transplant Center.
Shamsaeefar A; Kazemi K; Nikoupour H; Moosavi SA; Mashhadiagha A; Sayadi M; Gholami S; Motazedian N; Nikeghbalian S; Malekhosseini SA
Transpl Immunol; 2023 Jun; 78():101827. PubMed ID: 37003498
[TBL] [Abstract][Full Text] [Related]
15. Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.
Tsai YF; Chen HP; Liu FC; Liu SH; Chen CY; Cheng CW; Lin JR
Oncotarget; 2016 Dec; 7(50):83784-83794. PubMed ID: 27626495
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
17. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
18. De novo malignancies after liver transplantation: a major cause of late death.
Fung JJ; Jain A; Kwak EJ; Kusne S; Dvorchik I; Eghtesad B
Liver Transpl; 2001 Nov; 7(11 Suppl 1):S109-18. PubMed ID: 11689783
[TBL] [Abstract][Full Text] [Related]
19. Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges.
Otte JB
Liver Transpl; 2016 Sep; 22(9):1284-94. PubMed ID: 27096329
[TBL] [Abstract][Full Text] [Related]
20. Burden of de novo malignancy in the liver transplant recipient.
Chandok N; Watt KD
Liver Transpl; 2012 Nov; 18(11):1277-89. PubMed ID: 22887956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
